Marker Therapeutics, Inc. (MRKR)
NasdaqCM - NasdaqCM 延遲價格。貨幣為 USD。
加入追蹤清單
收市：04:00PM EDT
收市後：
| 前收市價 | 4.2000 |
| 開市 | 4.3300 |
| 買盤 | 3.1400 x 200 |
| 賣出價 | 5.3300 x 200 |
| 今日波幅 | 4.1500 - 4.4250 |
| 52 週波幅 | 1.1600 - 9.6800 |
| 成交量 | |
| 平均成交量 | 18,172 |
| 市值 | 37.57M |
| Beta 值 (5 年，每月) | 1.54 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.5900 |
| 業績公佈日 | 2024年5月13日 - 2024年5月17日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 11.75 |
BenzingaCancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. The company has prioritized MT-601 in chimeric antigen receptor (CAR) relapse patients with lymphoma. The FDA cleared Marker's Investigational New Drug application for a Phase 1 trial to investigate MT-601 combined with first-line chemotherapy in patients with pancreatic cancer. The clinical adva
